Leronlimab will have effect through all stages of

Leronlimab will have effect through all stages of NAFLD and NASH. In very early NAFLD stages it may not be worthwhile to use leronlimab because it may not progress to NASH. As biomarkers increase at mid and late stage NAFLD then leronlimab would be warranted as a preventative. NASH trial first of course because an NAFLD trial would need a very large patient population.

The picture you have linked to is a little simplistic. Even with simple steatosis you'll see CCR5 and inflammatory conditions starting. At mid point NAFLD you'll see pathological conditions starting with a greater chance that it will continue and go into NASH.